ARTICLE | Company News
FDA approves Remicade for UC
September 16, 2005 12:45 AM UTC
The FDA granted marketing approval to Johnson & Johnson (JNJ) subsidiary Centocor for its Remicade infliximab to treat moderate to severely active ulcerative colitis (UC) in patients who have had an i...